Biochem/physiol Actions
Target IC50: 800 nM against cAMP-specific phosphodiesterase (PDE IV)
Reversible: no
Product does not compete with ATP.
Cell permeable: yes
Primary TargetPDE IV
General description
Cell permeable, selective competitive inhibitor of cAMP-specific phosphodiesterase IV (IC50 = 800 nM). Rolipram does not inhibit PDE I or PDE II, even at concentrations as high as 100 µM. It is only a weak inhibitor of PDE III (IC50 = 100 µM). A rolipram-insensitive phosphodiesterase IV subtype is also known to exist.
A cell-permeable, selective inhibitor of cAMP-specific phosphodiesterase (PDE IV; IC50 = 800 nM). A rolipram-insensitive PDE IV subtype is also known to exist. Also inhibits NF-κB and NFAT activation in Jurkat and primary T cells.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Other Notes
Navarro, J., et al. 1998. J. Virol. 72, 4712.Truong, V.H. and Muller, T. 1994. FEBS Lett.353, 113.Underwood, D.C., et al. 1994. J. Pharmacol. Exp. Ther. 270, 250.Moore, J.B., Jr., et al. 1991. Biochem. Pharmacol.42, 679.Reeves, M.L., et al. 1987. Biochem. J. 241, 535.Schneider, H.H., et al. 1986. Eur. J. Pharmacol.127, 105.
Packaging
5 mg in Plastic ampoule
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). DMSO stock solutions are stable for up to 6 months at -20°C.
Warning
Toxicity: Irritant (B)
This product has met the following criteria: